Stryker Corp., US8636671013

Stryker stock keeps robot production in U.S. over IP concerns

Published on 11/19/2026 at 14:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Stryker stock is in focus as CEO Kevin Lobo defends U.S. robot production over intellectual-property concerns. The group is expanding into soft-tissue surgery.

Robotics strategy gains prominence

  • Stryker plans to keep orthopedic robot production in the United States because management considers intellectual-property protection a major concern.
  • The Mako system has supported two out of three Stryker knee replacements and has been used in 2.5 million procedures across 47 countries.
  • Stryker's roughly 400 million US dollar investment in CMR Surgical expands its reach into soft-tissue robotic surgery.
Stryker Corp., US8636671013, Illustration mit AI erstellt.

On Monday, November 16, Stryker Chair and CEO Kevin Lobo said the company has no plans to manufacture orthopedic surgical robots in China, citing intellectual-property concerns. Fortune published the comments on Tuesday, November 17, after Lobo spoke at the Fortune 500 Innovation Forum in Detroit.

Robotics strategy meets IP concerns

Lobo said Stryker builds its orthopedic robots in the United States and ships them worldwide. He described intellectual-property protection as a major concern in China, while saying the company continues to assess opportunities involving robotics for other parts of the anatomy.

The comments underline the growing role of robotics in Stryker's orthopedic business. Lobo said two out of every three Stryker knee replacements now use the Mako system. He also said Mako had been used in 2.5 million procedures across 47 countries. The system uses a surgical plan based on a CT scan and haptic boundary controls that restrict the robotic arm's movement.

CMR expands soft-tissue reach

Stryker's robotics strategy extends beyond orthopedics through its agreement with CMR Surgical. In October, Stryker agreed to invest roughly 400 million US dollars in preferred equity in the London-based company. The arrangement gives Stryker exclusive US sales rights for CMR's Versius soft-tissue robot and an exclusive option to acquire CMR later, subject to regulatory approvals.

Management presented Versius as a smaller system aimed at procedures such as gallbladder removal and hernia repair. The investment gives Stryker an additional route into soft-tissue surgery while the company works through slower hip and knee demand. The CMR transaction is strategic background to Lobo's latest comments rather than a newly announced deal.

Stock context for investors

Stryker stock traded at 289.90 euros on Lang & Schwarz at 14:04 CET on Thursday, November 19, 2026, 0.12 percent above the Xetra close of Wednesday, November 18, 2026. The quote places the shares modestly above the previous Xetra session as investors assess the company's push to extend robotics across more surgical specialties.

The strategy offers potential access to higher-value procedures and recurring technology use, but its execution depends on regulatory clearance, hospital adoption and Stryker's ability to integrate new platforms without weakening operating performance. The company has not provided a completion date for the CMR option.

Stryker Corporation

  • ISIN: US8636671013
  • Primary listing: New York Stock Exchange
  • Lang & Schwarz quote: 289.90 euros on November 19, 2026 at 14:04 CET
  • Xetra close: 289.55 euros on November 18, 2026
  • Change versus Xetra close: 0.12 percent higher

US investors can follow the broader market through the S&P 500 market overview.

More news and analyses on Stryker stock

Disclaimer...
en | US8636671013 | STRYKER CORP. | boerse | 70536183 | bgmi